How tirzepatide is used for weight loss — and what the evidence actually shows

The biggest myth: tirzepatide is just another GLP-1 injection

Most people researching weight-loss injections have come across semaglutide first. So the natural assumption is that tirzepatide is doing the same thing, slightly differently packaged. It isn't, and that distinction matters clinically.

Semaglutide targets a single receptor pathway, GLP-1. Tirzepatide targets two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a gut hormone that plays its own role in regulating appetite and fat storage, and stimulating both pathways together appears to produce a more pronounced effect than either alone. The NHS medicine page for tirzepatide describes it as acting on these two receptors to reduce hunger and slow the movement of food through the stomach.

That dual action is why the trial results look different. In SURMOUNT-1, participants on 15 mg tirzepatide lost an average of roughly 20–21% of their starting weight over 72 weeks, figures that sit well above what earlier single-pathway medicines produced at standard doses. These were adults with obesity and no diabetes, following a reduced-calorie diet alongside treatment. The medicine is not doing the work alone; the lifestyle component is part of what it's licensed alongside.

If you want to understand the full clinical picture, the tirzepatide and weight loss overview on this site covers the evidence in more detail, and our guide to tirzepatide use for weight loss explains how it fits into a broader treatment plan.

Who tirzepatide is actually licensed to treat (and where the prescriber's judgement comes in

The UK licence covers adults with a BMI of 30 or above, or those with a BMI of 27 or above who have at least one weight-related condition) high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea, or cardiovascular disease, for example. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

NICE's appraisal of tirzepatide (TA1026, published December 2024) recommends it on the NHS for adults with a BMI of 35 or above alongside at least one weight-related comorbidity, within structured NHS services as they roll out, and our summary of what the NICE tirzepatide guidance means for weight loss breaks down the practical implications of that decision. That's a narrower set of criteria than the licensed population, which is why many people who are eligible under the SmPC don't currently qualify for NHS treatment.

Meeting the BMI threshold is a starting point, not a guarantee. A prescriber reviews the full picture: other medicines you take, relevant medical history, and whether any contraindications apply. Pregnancy, breastfeeding, and trying to conceive all mean tirzepatide is not recommended; neither is it licensed for under-18s. Certain conditions (including a history of medullary thyroid carcinoma) require careful discussion before any GLP-1 medicine is considered.

A useful one-minute habit: before any online consultation, check that the pharmacy you're considering is listed on the GPhC pharmacy register. It takes seconds and confirms you're dealing with a regulated service.

What tirzepatide's dosing schedule is designed to do

Treatment starts at 2.5 mg once weekly. That first pen is not a therapeutic dose in the usual sense, its job is to let your system adjust gradually and reduce the likelihood of nausea. The prescriber then steps the dose upward, usually every four weeks, through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg. Not everyone will reach the highest strength; the right maintenance dose is the one your prescriber determines suits you.

More detail on how this titration works in practice is set out on the tirzepatide dosing page, including what drives decisions to hold at a particular strength.

Each pen contains four weekly doses. Injections go into the abdomen, thigh, or upper arm, rotating the site each week. The pen is stored in the fridge (between 2 and 8°C) and there is a limited window during which it can be kept at room temperature. The exact window is specified in the Patient Information Leaflet that comes with your supply; always use that as your reference rather than relying on general figures online.

You can explore the broader range of weight-loss treatment options available in the UK to understand where tirzepatide sits relative to other approaches.

Side effects to know about, and when to act quickly

The most frequently reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping. These are typically most noticeable in the first few days after starting treatment or after a dose increase, and for most people they settle within one to two weeks. Fatigue, headache, dizziness, and mild injection-site reactions also appear in the trials.

There are symptoms that need prompt medical attention rather than a wait-and-see approach. Severe stomach pain that radiates through to the back, with or without vomiting, requires urgent assessment, pancreatitis is a known but infrequent risk with GLP-1 medicines, and the MHRA's January 2026 Drug Safety Update highlighted this as a symptom profile that should not be dismissed. Signs of a serious allergic reaction, symptoms of gallbladder problems, or significant dehydration from persistent vomiting or diarrhoea also warrant a call to 111 or a visit to A&E.

Suspected side effects can be reported through the MHRA Yellow Card scheme, which accepts reports from patients directly alongside those from healthcare professionals.

Tirzepatide carries a Black Triangle (▼) designation in the UK, meaning the MHRA actively collects additional safety data. That's standard for newer medicines, not a sign of unusual risk, but it does underscore why prescriber oversight throughout treatment matters.

Our clinical team reviews every consultation personally, if questions come up after you start treatment, our prescribers are reachable seven days a week through aftercare support. If you'd like to understand how tirzepatide compares against the evidence for semaglutide, the results breakdown walks through the head-to-head data. For context on what private treatment costs and what a legitimate price should include, the Mounjaro pricing page sets that out plainly.